Consultant, Women's Health

Consultant, Women's Health Focused on educating women about menopause, bio-identical estrogen and progesterone,

11/11/2025

Medical education doesn’t pay much attention to nutrition, so most practicing physicians don’t, either.

11/11/2025

What Is Osteoporosis?
Osteoporosis is a disease you get when you lose bone faster than you make it. “Osteo” means bone, and “porosis” means porous (full of holes). The bone loss of osteoporosis makes your bones weak, brittle, and fracture easily.

Symptoms
2/12
Symptoms
You probably won’t have any symptoms in early-stage osteoporosis. Once your bones get weak enough, you might start having back pain from fractured or collapsed vertebrae. You may also start leaning forward in a stooped position and measure an inch or two less than before your bone loss.

Fractures
3/12
Fractures
Sometimes a bone fracture is the first way you know you have osteoporosis. Fractures can happen in any bone, but are most common in your hip, wrist, and spine. It doesn't take a fall to cause a fracture in weak bones. You can get one climbing stairs, lifting heavy objects, or even leaning forward. These kinds of fractures can cause long-term chronic health problems.

Causes
4/12
Causes
Estrogen is a hormone that helps you build and protect bone. When estrogen levels are low you lose bone. You also lose bone during and after menopause when your ovaries stop making estrogen. Your risk of getting osteoporosis goes up if you didn’t build enough bone as a child from an eating disorder, lack of vitamin D or calcium, lack of exercise, or another health problem.

Risk Factors
5/12
Risk Factors
Osteoporosis can happen at any age, but it’s most common in adults over 50. Women are four times more likely to get it than men. Your chance of bone loss goes up if you’re Asian or white, have a small body frame, and if you have a family member with osteoporosis -- especially if that family member fractured a bone.

Other Risk Factors
6/12
Other Risk Factors
As your s*x hormones (testosterone and estrogen) go down with age, your risk goes up. Some cancer treatments also lower these hormones. Too much thyroid hormone or an overactive parathyroid or adrenal gland can bump up your risk, as can other conditions like celiac, kidney, or liver disease, lupus, inflammatory bowel disease, and rheumatoid arthritis. Steroids, like prednisone, can also increase your risk

11/10/2025

Again this article ignores many many research studies that show that Estrogen alone protects the heart, brain and bones..when you add synthetic progestin ..all the protection disappears..however, with bio-identical , natural progesterone, the heart , cognition and bone protection is sustained. Telling women to avoid Hormone Therapy without distinguishing the different formulations , routes of administration and the fact that one size does not fit all, is criminal. The last paragraph in this article is the most important paragraph..it should be front and center stage.

“F.D.A. Will Remove Black Box Warnings From Hormone Treatments for Menopause
The benefits of hormone replacement have been underappreciated, Dr. Marty Makary, the agency’s commissioner, said on Monday. Critics described evidence for the change as insufficient.

Listen to this article · 5:11 min Learn more
A close-up view of an orange pill bottle with greenish pills spilling out of it onto an off-white surface.
Estrogen pills used to treat menopause symptoms. Many hormone treatments have carried prominent warnings since 2003, when large trials found that oral combinations of estrogen and progestin raised the risks of blood clots and breast cancer.Credit...Photo Researchers, Inc./Science Source
Roni Caryn Rabin
By Roni Caryn Rabin
Nov. 10, 2025, 12:13 p.m. ET
The Food and Drug Administration will remove the so-called black box warning from all hormone replacement products containing estrogen, Dr. Marty Makary, the agency’s commissioner, announced on Monday.

The labels will be rewritten with age-specific guidance indicating that there are long-term health benefits if treatment is begun within 10 years of the onset of menopause.

The changes, expected within six months, represent a radical turnabout in what women have been told about hormone replacement therapy.

In 2003, large government-run clinical trials concluded that hormone pills did not protect against heart disease or dementia, and in fact raised the risk of blood clots and breast cancer. Medical guidelines since then have told women to use hormones only sparingly for menopausal symptoms like hot flashes.

Dr. Makary, long a champion of the treatment, asserted on Monday that in fact hormones can reduce cardiovascular disease and cognitive decline, and can improve bone health in postmenopausal women.

“The long-term health benefits have been largely misunderstood,” Dr. Makary said. “Hormone replacement therapy may improve the health outcomes of women at a population level more than any other intervention, arguably, with the exception of antibiotics or vaccines.”

Your Questions About Menopause, Answered

Card 1 of 8
What are perimenopause and menopause? Perimenopause is the final years of a woman’s reproductive years that leads up to menopause, the end of a woman’s menstrual cycle. Menopause begins one year after a woman’s final menstrual period.
What are the symptoms of menopause? The symptoms of menopause can begin during perimenopause and continue for years. Among the most common are hot flashes, depression, ge***al and urinary symptoms, brain fog and other neurological symptoms, and skin and hair issues.
How can I find some relief from these symptoms? A low-dose birth control pill can control bleeding issues and ease night sweats during perimenopause. Avoiding alcohol and caffeine can reduce hot flashes, while cognitive behavioral therapy and meditation can make them more tolerable. Menopausal hormone therapy and the selective serotonin reuptake inhibitor paroxetine can also ease some symptoms.
What is Veozah? Veozah is the first nonhormonal medication to treat hot flashes in menopausal women; it was recently approved by the F.D.A. The drug targets a neuron in the brain that becomes unbalanced as estrogen levels fall. It might be particularly helpful for women over 60 because, at that age, starting hormonal treatments can be considered risky.
How long does perimenopause last? Perimenopause usually begins in a woman’s 40s and can last for four to eight years. The average age of menopause is 51, but for some it starts a few years before or later. The symptoms can last for a decade or more, and at least one symptom — vaginal dryness — may never get better.
What can I do about vaginal dryness? There are several things to try to help mitigate the discomfort: lubricants, to apply just before s*xual in*******se; moisturizers, used about three times a week; and/or estrogen, which can plump the vaginal wall lining. Unfortunately, most women will not get 100% relief from these treatments.
What is primary ovarian insufficiency? The condition refers to when their ovaries stop functioning before the age of 40; it can affect women in their teens and 20s. In some cases the ovaries may intermittently “wake up” and ovulate, meaning that some women with primary ovarian insufficiency may still get pregnant.
Fact, or fiction? We asked gynecologists, endocrinologists, urologists and other experts about the biggest menopause misconceptions they had encountered. Here’s what they want patients to know.
Asked whether hormone use was safe for all women, he added that any patient with a predisposition to blood clots or a history of breast cancer fueled by hormones should avoid it. He acknowledged that there may be other contraindications.

Critics opposed to removing the warning, the strongest kind the F.D.A. issues, had urged Dr. Makary to convene a scientific advisory panel to carry out a careful assessment of the evidence before making any changes to the label.

“Removing the black box and putting warnings in a lengthy label that many doctors and most patients will not read is taking women’s health backward,” Diana Zuckerman, a scientist and president of the National Center for Health Research, said on Monday.
“The claim that hormones for menopause is the best way to improve the health of women is inconsistent with years of research and will harm millions of women,” Dr. Zuckerman said. “There are many better ways to reduce the chances of osteoporosis, heart disease, cancer and dementia than hormone therapy for menopause.”

Hormone use has plummeted in recent decades. Even though estrogen is considered the most effective treatment for alleviating menopausal symptoms like hot flashes, night sweats and sleep loss, some doctors say that many women who could benefit avoid the treatment.

Hormone therapy has been used to relieve menopausal symptoms since the 1940s. By the 1980s, hormones were increasingly being prescribed to prevent cardiovascular disease and osteoporosis, as well, even in women well past menopause, despite concerns that the treatment might raise the risk of breast cancer.

The popularity of hormones was driven largely by observational studies indicating that hormones protected women from heart disease.( False.. many well-designed research studies were undertaken)

But large randomized trials subsequently tested this hypothesis, and concluded that there were no benefits to hormone replacement therapy in terms of heart attacks — and that it actually increased the risk of blood clots and strokes.
The trials also concluded that combined hormones — progestin and estrogen — in pill form increased the risk of breast cancer. But the danger to individual women was small, especially in early menopause, and there was no increase in breast cancer with estrogen alone, which lowered heart attack risk among women in their 50s.

Hormones also offered some benefits, reducing osteoporosis-related bone fractures and colorectal cancer.

Critics have questioned the conclusions and the methodology of the government-sponsored trials. Some of the risks were of borderline significance, they said, and women who wanted to reap long-term benefits from hormone treatment should initiate it soon after the onset of menopause.

Many doctors who treat menopausal women had pushed for removing the black box warning from local vaginal estrogen products, noting that these are low-dose products applied topically, not oral formulations. These physicians argued that studies have shown minimal to no systemic absorption of hormones from such products.

But the risks and benefits of long-term use of vaginal estrogens are still unclear, because the studies have been of limited duration, some experts say.
The black box label currently on estrogen products says that oral estrogen, with or without progestin, should not be taken to prevent heart disease and increases the risk of probable dementia in women 65 and older, as well as blood clots and strokes.

he label warning says that combined estrogen and progestin pills — a formulation used to offset the risk of uterine cancer — increases the risk of breast cancer.

The label notes, however, that these risks were found in trials of specific hormone formulations, and that the risks may not carry over to products with different formulations or to topically applied or low-dose prod

11/02/2025

🚨 New research reveals microplastics buried centuries before we invented plastic.

Microplastics have officially made their mark—literally everywhere. A new study has found traces of these tiny pollutants buried deep in sediment layers dating back to the early 1700s, long before the industrial age or modern plastic production began.

European researchers examined lake sediments in Latvia and discovered that even layers untouched by modern humans were contaminated, challenging the idea that microplastics can be used to mark the start of the Anthropocene Epoch. Their findings, published in Science Advances, suggest that plastic pollution has permeated the planet in ways we still don’t fully understand.
The implications are sobering: microplastics aren’t just in our oceans and food—they’re in the air we breathe, in the snow of Antarctica, and even inside our bodies.

Scientists continue to explore how these particles travel, their health impacts, and whether we can ever remove them from our environment. From experimental filters to trees that may help clean polluted soil, the fight against microplastic contamination is just beginning.

Source:
Adarlo, Sharon. “Microplastics Found in Sediment Layers Untouched by Modern Humans.” Futurism, 23 Feb.

11/02/2025

FDA-Approved HT
Numerous FDA-approved hormone preparations are available for the treatment of menopausal symptoms. These include those that fulfill the definition of bioidentical and those that are clearly not bioidentical. Products can contain only estrogen (synthetic conjugated estrogens; natural, nonhuman conjugated estrogens; or plant-derived bioidentical estrogens), only progestogens (synthetic progestin or bioidentical progesterone), or a combination of estrogen and progestin. Those that contain synthetic conjugated estrogens, conjugated estrogens (derived from the urine of pregnant mares), or progestins are not bioidentical to the endogenous human s*x steroid hormones.12
FDA-Approved BHT
Currently, FDA-approved products containing bioidentical estrogen and progesterone are available. Bioidentical estrogen derived from plant sources (17β-estradiol) is available in pills, patches, sprays, creams, gels, and vaginal tablets. These preparations differ from custom CBHT preparations in that they are carefully controlled and regulated formulations (eg, oral, transdermal, and vaginal preparations), they are manufactured under strict standards, and their effects are subjected to scientific scrutiny.13 Numerous peer-reviewed publications have documented the beneficial effects of various doses of FDA-approved estrogen products on vasomotor symptoms, hot flashes, bone density, uroge***al atrophy, and fracture prevention.14 In contrast, large-scale, randomized, controlled studies have not been conducted for custom CBHT.15
Progesterone bioidentical to that found in humans is currently available in certain FDA-approved preparations (as oral micronized progesterone in oil or as vaginal progesterone gel) (Table 1).
TABLE 1.
FDA-Approved Bioidentical Hormones

10/28/2025
10/17/2025

Again..Hormone replacement is safe IF
You do not use synthetic progestin..the culprit ..use bio-identical progesterone instead..education your prescriber!!

Menu
Healio
Account


Close Searchbar

Q&A: New menopause training initiative ‘will give future providers the skills they need’

October 10, 2025
4 min read
ByAndrew (Drew) Rhoades
BySusan Scanlon, MD, MSCP, FACOG
Fact checked byCarol L. DiBerardino, MLA, ELS

Save

Share
Key takeaways:
Women in menopause face complex medical issues, making comprehensive care critical, an expert told Healio.
The Menopause Society launched an initiative to educate providers about menopausal care.

October is Menopause Awareness Month, an initiative that aims to educate people about the physiological process of the condition, how it impacts women and ways to support them.

Awareness of menopause in clinical practice is rising, as indicated by an increase in formal diagnoses from 2018 to 2022, according to a report from the Health Care Cost Institute (HCCI).

OBGYN1025Scanlon_IG1
Yet, menopause “remains one of the most overlooked and underserved areas in medicine,” according to The Menopause Society. The HCCI report revealed that only 25% of women who sought care for menopause-related issues received treatment.

The Menopause Society in June took action to combat this gap by launching their NextGen Now Initiative, a $10 million training program “designed to equip current and the next generation of health care professionals with the knowledge, tools, and support needed to improve the care of midlife women,” a press release said.

The Menopause Society noted their goal is to reach 25,000 health care providers (HCPs) over the next 3 years. According to the release, the initiative “will include development and implementation of curated and immersive training experiences for HCPs, study materials, scholarships, and new position statements and consensus recommendations, among other resources.”

Healio spoke with Susan Scanlon, MD, MSCP, FACOG, Menopause Society-certified practitioner, president and chairman of the Board of Midwest Center for Women’s HealthCare and medical director at Unified Women’s Healthcare, to learn more about gaps in menopause care, what the initiative means for HCPs and more.

Healio: Why is menopause one of the most underserved areas in medical education?

Scanlon: Traditionally, menopause has not been a primary topic in medical school and residency training. Only 31% of OB/GYN residency training programs have included menopause on the curriculum, and of those that do, most include only one or two lectures on the topic. This is most likely due to the misconception that the menopausal transition is just a normal part of aging, and therefore, the benefit of education about the growing medical risks to women during this transition has been overlooked. Thankfully, with recent greater awareness of the significant medical risks women face during menopause, such as heart disease and osteoporosis, the medical community is starting to expand its medical curriculums. My daughter is in her first year of medical school now at Emory, and menopause is on the curriculum.

Healio: What does the $10 million initiative mean for both current providers and future medical trainees?

Scanlon: The $10 million initiative was launched recently by The Menopause Society. For current providers, there will be an expansion of CME opportunities that will enable them to fill in the gaps in their knowledge base on menopause and midlife women's health. The goal is for providers to have better training and education so they can provide the best possible proactive and preventive care to their patients, as well as combat the confusing misinformation that both providers and patients face. Financial resources will be allocated through this initiative to update menopause clinical guidelines and fund the CME programs.

For future providers (medical students and residents), the initiative aims at providing mentorship and specialized training in menopause. This will give future providers the skills they need to address the complex medical conditions many midlife patients experience. This can translate to better care and outcomes for patients.

Healio: What innovative tools are available to close knowledge gaps?

Scanlon: Tools available to close knowledge gaps include CME programs and mentor programs. Consider attending The Menopause Society annual meeting, learning about their NextGen Now initiative and registering to receive their practice pearls and position statements to help stay current with midline women's health recommendations and guidelines.

Healio: Why is comprehensive, evidence-based menopause care critical to improving quality of life?

Scanlon: Women in menopause face complex health issues that can impact their quality of life, sense of well-being and long-term health, so comprehensive evidence-based menopause care is critical to help women lead their best and healthiest lives. From prevention of heart disease and osteoporosis to management of vasomotor symptoms and s*xual health challenges, adequate research is needed, and dissemination of that information to all providers who take care of women is critical to helping women lead their healthiest and most satisfied life.

Healio: What is a common misconception about menopause in the medical community? What do you want providers to know about this?

Scanlon: A common misconception about menopause is that hormone therapy is dangerous for all women. This primarily stemmed from the early misinterpretation of the data from the Women’s Health Initiative released in 2002. As a result, so many women over the last 20 years missed the opportunity of the benefits of hormone therapy. For nearly 15 years, I have been a certified menopause practitioner through The Menopause Society, and the truth is that most women can use hormone therapy. There are a few guidelines and restrictions, such as breast cancer, clotting disorders and liver disease, but overall, most midlife women would benefit from hormone therapy for their long-term health and quality of life.

For more information:
Susan Scanlon, MD, MSCP, FACOG, can be reached at primarycare@healio.com.

10/12/2025

“Let's address what often gets missed in primary care. Perimenopause and menopause are powerful disruptors of sleep in your female patients. Up to 90% of your female patients are going to struggle with sleep. During these transitions, they may have trouble falling asleep. They may have trouble staying asleep. They may have early-morning awakenings. They also will have vasomotor symptoms, such as night sweats. They also are more prone to developing restless leg syndrome, and this may be a new change to their sleep pattern, meaning they develop new-onset insomnia. These aren't just minor annoyances. They can tank quality of life, they can worsen your mood, and they can impact your cardiometabolic health. So, what's driving this?

Well, it's fluctuating and declining hormones, specifically progesterone and estrogen. Progesterone is, in particular, very, very significant in terms of being our "chill out" hormone or the hormone that helps us get better, more restful sleep. As women, both progesterone and estrogen can also contribute to healthier breathing at night. So as these hormones dip, sleep fragmentation as well as sleep-disordered breathing (AKA obstructive sleep apnea) become much more common. And this can occur even in women who are of normal weight.
And here's the twist: Women with sleep apnea may frequently present with symptoms that overlap with classic perimenopausal complaints, so they may not present like men. They may be describing chronic insomnia type of complaints — disrupted sleep, maybe just simply being unrefreshed by sleep or feeling fatigued and not quite knowing why — but they may not have the classic symptoms of being a loud snorer or having excessive daytime sleepiness, such as what their male counterparts are more likely to complain of.

This means that female patients may be presenting not only with symptoms of insomnia, but also have underlying obstructive sleep apnea — a term that we call COMISA: comorbid OSA with insomnia. COMISA can be tricky and is often overlooked.

So, what is it that you can do whenever insomnia or disrupted sleep or fatigue — nonspecific sleep complaints — appear in women who are over the age of 35? I want you to have a very low threshold for either referring for a formal sleep consultation or ruling out obstructive sleep apnea with a home sleep apnea test or a polysomnogram. I also encourage you to discuss hormonal (like traditional hormone replacement therapy) type of treatments and nonhormonal treatments. These may include neurokinin B antagonists, gabapentin, SSRIs, SNRIs, and — believe it or not — cognitive-behavioral therapy for insomnia, which has been shown to really improve vasomotor symptoms as well as insomnia symptoms in women going through the perimenopausal/menopausal transition.

For those with obstructive sleep apnea, please educate that CPAP is not the only game in town. It may be the gold standard, but there are other treatments that may be very effective for your patients, including oral appliance therapy, hypoglossal nerve stimulation, GLP-1s for treatment of patients who are both obese as well as have moderate to severe obstructive sleep apnea. In addition, there are emerging therapies that are probably not too far along on the horizon, including a medication that might be used to help to strengthen the upper airway musculature and improve muscle tone, thereby improving obstructive sleep apnea.

So this is my call to action to you. Sleep problems in perimenopausal women are multifactorial and they demand a collaborative and highly individualized approach. …proactively screen for sleep issues, educate , and partner with your sleep specialists, your dental medicine professionals, as well as your menopause specialist .

By recognizing atypical presentations of sleep issues and empowering women with a full spectrum of treatment options, you can truly transform your sleep health .

10/09/2025

Menopausal Hormone Therapy Lowers Upper GI Cancer Risk
Becky McCall, MSc, MScPh
October 08, 2025
Summarize
BERLIN — Women who use menopausal hormone therapy (MHT; ie, hormone replacement therapy ) have an up to 30% reduction in the risk of developing esophageal and gastric cancers compared to nonusers, according to a large population-based study across five Nordic countries. The association appeared strongest for combined estrogen-progestin and systemic formulations.

“This is one of the largest and most comprehensive studies to date supporting the hypothesis of an inverse association between MHT and risk of esophago-gastric cancer,” said Victoria Wocalewski, MD, from the Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, who presented the findings at United European Gastroenterology (UEG) Week 2025.

There was a decreased risk for all investigated cancers in MHT users, but the strongest association was observed for esophageal adenocarcinoma (EAC), said Wocalewski. In addition, “there were discrete dose-dependent results for [EAC] and gastric adenocarcinoma (GAC) but not for esophageal squamous cell carcinoma (ESCC).”

Large Population-Based Study

Previous research has suggested that hormonal changes could partly explain the male predominance in esophageal and gastric cancers, but evidence from large, well-controlled datasets has been limited.

“Cancer rates in women increase significantly after age of 60, so it has been hypothesized that this pattern is linked to declined levels of estrogen that comes with menopause,” said Wocalewski, explaining the rationale for the study.

“Some studies looking at MHT use have indicated a possible protective effect, but with some contradictory results and type-specific variations,” Wocalewski noted. “Our study aimed to investigate these previous findings using a larger study sample.”

The population-based case-control study drew on prospectively collected data from the NordGETS database including national prescription, cancer, and population registries in Denmark, Finland, Iceland, Norway, and Sweden spanning 1994-2020. In total, 19,518 women with esophago-gastric cancer were compared with 195,094 controls randomly selected from the general population, and matched for age, calendar year, and country (in a 1:10 ratio). Women were 45 years or over with a diagnosis of EAC, ESCC, or GAC.

09/15/2025

Heart Disease Differs in Women
Usual Tests, Drugs May Not Work Well
By Rob Stein
Washington Post Staff Writer
Sunday, August 8, 2004; Page A01
At first, Kathy Kastan's symptoms just seemed weird. An avid athlete, she would get oddly tired, struggle to catch her breath, and wince at the pain in her shoulder and back when she exercised. She tried shaking it off, but the problems kept nagging her, so the 41-year-old consulted a cardiologist.
"He said, 'You're healthy as a horse. I never want to see you again,' " said Kastan, who lives in Cordova, Tenn.

But she got worse -- so bad that crushing chest pain knocked her down every time she tried to work out. Finally, she went to specialists who discovered that Kastan did have serious heart disease -- just not the familiar, clogged-up-artery kind. Instead, her arteries would mysteriously spasm, strangling the blood flow to her heart muscle.
"It's amazing how many women have been through this. They have these symptoms, and nobody can figure out what's wrong," she said. "I was one of the lucky ones. I escaped an actual heart attack."

Doctors are starting to realize that many women probably have Kastan's kind of heart disease, as well as other forms that differ in essential ways from the well-known pattern that strikes most men.

This new understanding -- that heart disease may be a fundamentally different disease in many women -- has far-reaching implications for medicine's ability to defend women against the nation's No. 1 killer. Contrary to persistent misconceptions, heart disease claims the lives of more women than men.
"The whole disease is poorly understood in women, from the expression of the symptoms all the way down to some of the basic mechanisms," said Carl J. Pepine, a cardiologist at University of Florida's College of Medicine in Gainesville. "The disease has a very broad spectrum, and more men are at one side and more women are at the other side."

Instead of one main blockage, arteries in many women go into spasm or have smaller, easily missed buildups along their entire lengths, which can be just as dangerous as one big one. And often the problems lie not in the major arteries that nourish the heart muscle but in the frequently overlooked smaller branches.

These differences, frequently found in younger women, could help explain why the symptoms are often so different than in men, why women are often misdiagnosed -- or never diagnosed -- why they commonly are not treated until much later, and why women are more likely to die from their heart disease even when they are treated. The standard tests, drugs and procedures simply may not work as well for many women.
"We are just now starting to describe this really for the first time," said C. Noel Bairey Merz, a heart expert at Cedars-Sinai Medical Center in Los Angeles. "We hear about how women are treated less aggressively than men, and how they eventually have worse heart attacks and are more likely to die with their heart disease. We can see how this could culminate in that way."

This new understanding is emerging only now because heart disease research has traditionally focused almost exclusively on men. Experts assumed that women's tendency to fare so poorly was the result of not being treated as early or as thoroughly as men.

"In the past, we had the assumption of equality -- that everything was equal between the genders and there were no differences," said George Sopko of the National Heart, Lung, and Blood Institute. "Now that's beginning to unravel."
Experts stress that most women who get heart disease are struck by the same form that hits men, which can be prevented and treated the same way. But a new generation of research is urgently needed, Bairey Merz and other experts say, to better understand the other ways women's arteries start to become diseased, zero in on the most important risk factors, develop new diagnostic tests and find treatments tailored specifically for women.
"Men and women are very similar, but like many other areas of health, when we've bothered to do the research there are differences that sometimes can have clinically significant importance," Bairey Merz said.

One of the main sources of this new understanding is the federally funded Women's Ischemia Syndrome Evaluation (WISE) study, which is tracking about 1,000 women in Florida, Pennsylvania and Alabama who have chest pain or other symptoms but who mostly seem fine on standard tests.

"In general, people think these ladies are crazy. They are not infrequently told they are nuts," Bairey Merz said. They often are sent to stomach specialists or for psychotherapy and end up in a maddening hunt for the source of their ills until finally, weeks, months or years later, they are in an emergency room with a heart attack.
The WISE study found that in nearly half of these women, their hearts are not getting enough blood, and one-third are likely to go on to have a heart attack or other serious heart problems -- three times the usual risk.

"Women appear more likely to more diffusely lay out their plaque throughout the wall of the artery, whereas men are more likely to lay it down a lumpy-bumpy pattern," Bairey Merz said. "This could explain the delayed diagnoses, the missed diagnoses, the never diagnoses."
The reason for this difference is unclear, but it may be a result of women's unique hormonal chemistry and differences in how women's arteries respond to stress.

"What we believe is that women's bodies remodel their arteries to accommodate the . . . plaque," Pepine said. "If you think about the whole female picture, they are designed to do that. They remodel their arteries to accommodate blood flow when they are pregnant."
Detailed studies of the arteries of women who died of heart attacks have found that the disease often looks much different in women in another way.
"In men, it's like a sore, like a pimple, that breaks and leads to the formation of a blood clot, that causes a heart attack," said Renu Vermani of the Armed Forces Institute of Pathology in Washington. "In women, we don't see this pimple. We see erosion. It's a malformation -- like a scab, like a scar."
Vermani speculates that when arteries spasm, the innermost lining, called the endothelium, momentarily rubs against itself. "Over time, that causes it to erode," he said. "The endothelium is disturbed, it's eroded, which leads to clot formation."
Doctors have long known that women are prone to blood vessel spasms and the ailments they cause, such as migraine headaches. When it happens to an artery feeding the heart, it produces pain or, in severe instances, a heart attack.

"It's like putting a rubber band around the artery: It narrows so that you can't get enough blood to supply the muscle to keep it viable," said Marianne J. Legato, a women's health expert at Columbia University.
The same bad actors that cause better-known forms of heart disease -- high cholesterol, high blood pressure, smoking, obesity -- may also damage the endothelium, making arteries prone to spasms or to diffuse plaques that diminish their ability to dilate properly. But there may be other factors that are particularly dangerous for women.

Because estrogen plays a role in processing nitric oxide, which helps arteries function properly, the endothelium may suffer when estrogen levels wane due to menopause. Another key player may be inflammation -- an overreaction by the immune system.

"Let's say you have somewhat high cholesterol and just slightly high blood pressure. The likelihood would be that you should have a low risk," Sopko said. "However, if you take some of these novel risk factors, like inflammation, it is possible that they act as amplifiers . . . that are gender-specific or gender-related."

Some researchers suspelevels.ct that the crucial oxygen-carrying protein in blood, hemoglobin, may also be important. Women tend to have less hemoglobin than men because of their monthly menstrual cycles, and low hemoglobin may further starve the heart muscle. Hemoglobin deficits may also reduce nitric oxide

"Hemoglobin turns out to be a major independent predictor of outcome," Pepine said.

Researchers have also found that in many women, plaques, spasms and tiny clots clog up the smaller branches of arteries, which are not routinely examined by doctors.

"They are very important, but we don't typically look at them," Bairey Merz said. "This appears to be dominantly a women's problem."

That was the case with Laura Luxemberg, 40, of San Diego. Bairey Merz diagnosed her with "microvascular disease" after she was initially told that her shortness of breath, headaches, chest tightness and other symptoms might be a digestive problem.

"That's what happened to my sister, too, three years ago. She went to the emergency room and was told to take Maalox," said Luxemberg, whose sister subsequently died from a heart attack.

One of the most disturbing implications is that many women would not be helped by the most aggressive treatments used to treat heart disease: surgery to bypass blocked major arteries and angioplasty, a procedure that wedges open clogged arteries and often keeps them open with tiny scaffolding called stents.

"If you don't have a discrete blockage, you have nothing to bypass. Sticking in a bypass may actually make things worse. You can't put a stent in the whole length of the vessel," said Sharonne N. Hayes, who runs a women's heart clinic at the Mayo Clinic in Rochester, Minn.

Women do respond to many of the drugs used to treat heart disease, including aspirin, cholesterol-lowering statins and vessel-dilating "ACE inhibitors," perhaps by reducing inflammation and improving blood vessel function.

But doctors such as Hayes have also started using new combinations of these drugs, as well as other, alternative treatments such as an amino acid called L-arginine, specifically to reduce inflammation and keep arteries functioning properly.

But much more research is needed, experts say. Researchers are developing ultrasound and other imaging techniques to help diagnose women earlier, for example. Drugs that boost hemoglobin might help treat them.
"Basically," Legato said, "we're doing a whole different kind of research, looking at women instead of just looking at men, which is what we have been wont to do."
© 2004 The Washington Post Company

Address

Greenwich, CT

Website

Alerts

Be the first to know and let us send you an email when Consultant, Women's Health posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Consultant, Women's Health:

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram